Prinaberel Explained

Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor.^[1] It is used in scientific research to elucidate the role of the ERβ receptor.^[2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.^[3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.^[4]

See also

• Diarylpropionitrile
• ERB-196
• Erteberel
• WAY-200070
• WAY-214156

External links

• Prinaberel - AdisInsight

Notes and References

1. Harris HA, Albert LM, Leathurby Y, etal . Evaluation of an estrogen receptor-beta agonist in animal models of human disease . Endocrinology . 144 . 10 . 4241–9 . October 2003 . 14500559 . 10.1210/en.2003-0550 . free .
2. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA . Reflections on the discovery and significance of estrogen receptor beta . Endocrine Reviews . 26 . 3 . 465–78 . May 2005 . 15857973 . 10.1210/er.2004-0027 . free .
3. Harris HA . Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential . Ernst Schering Foundation Symposium Proceedings . 2006/1. 1 . 149–61 . 2006 . 17824176 . 10.1007/2789_2006_021. 978-3-540-49547-5 .
4. Web site: Prinaberel - Wyeth phase change II, USA (endometriosis) . https://web.archive.org/web/20160307162827/https://business.highbeam.com/436989/article-1G1-146524305/prinaberel-wyeth-phase-change-ii-usa . dead . 2016-03-07 . 2006-06-05 . R & D Focus Drug News . 2012-05-20.